1. Scrip
  2. >>Business
  3. >>Deals

Infinity And MEI Re-evaluate Business Plans After Merger Falls Through

 
• By Jessica Merrill

MEI shareholders declined to approve the all-stock merger that would have combined the companies’ cancer pipelines.

broken heart
Infinity and MEI Pharma terminated a merger • Source: Shutterstock

Infinity Pharmaceuticals, Inc. and MEI Pharma, Inc. will be considering their next steps independently after a planned merger between the cancer drug developers fell apart. The companies announced the termination of their merger agreement on 24 July, one day after MEI stockholders voted against the plan in a special meeting. The combined company would have brought together MEI’s stronger cash position with Infinity’s later-stage cancer asset, which was poised to become the merged company’s lead development candidate.

MEI announced the results of its shareholder meeting on 23 July in which investors representing 47.86% of its outstanding shares...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By Manas Mishra

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By Manas Mishra

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.

More from Business

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”

Bayer Stokes Optimism With Guidance Update But Risks Remain

 
• By Aakash Babu

Even though the company’s pharmaceutical business continues to do well, navigating some key stress points will be crucial for Bayer.